Building a pattern detection model using a deep learning algorithm for data collected from manufacturing sites is an effective way for to perform decision-making and assess business feasibility for enterprises, by providing the results and implications of the patterns analysis of big data occurring at manufacturing sites. To identify the threshold of the abnormal pattern requires collaboration between data analysts and manufacturing process experts, but it is practically difficult and time-consuming. This paper suggests how to derive the threshold setting of the abnormal pattern without manual labelling by process experts, and offers a prediction algorithm to predict the potentials of future failures in advance by using the hybrid Convolutional Neural Networks (CNN)–Long Short-Term Memory (LSTM) algorithm, and the Fast Fourier Transform (FFT) technique. We found that it is easier to detect abnormal patterns that cannot be found in the existing time domain after preprocessing the data set through FFT. Our study shows that both train loss and test loss were well developed, with near zero convergence with the lowest loss rate compared to existing models such as LSTM. Our proposition for the model and our method of preprocessing the data greatly helps in understanding the abnormal pattern of unlabeled big data produced at the manufacturing site, and can be a strong foundation for detecting the threshold of the abnormal pattern of big data occurring at manufacturing sites.
Technology finance, which has attracted worldwide attention for the successful business development of small-and-medium enterprises (SMEs) or start-ups, has advanced an innovation or stagnation way-out resolution strategy for companies in line with the low-growth economic trends. Although the development of new technologies and the establishment of active R&D and commercialization strategies are essential factors in a company’s management sustainability, the activation of the technology market in practice is still in progress for its golden age. In this study, to promote a technology transfer-based company’s growth and to run technology-based various financial support activities, we develop and propose a new intelligent, deep learning-based technology valuation system that enables technology holders to estimate the economic values of their innovative technologies and further to establish a firm’s commercialization strategy. For the last years, the KIBO Patent Appraisal System (KPAS-II) herein proposed has been advanced by KIBO as a web-based, artificial intelligence (AI) and evaluation data applications valuation system that automatically calculates and estimates a technology’s feasible economic value by utilizing both the intrinsic and extrinsic index information of a patent and the commercialization entity’s business capabilities, and by applying to the discounted cash flow (DCF) method in valuation theory, and finally integrating with deep learning results based on the in-advance previously established patent DB and the financial DB. The KPAS-II proposed in this study can be said to have dramatically overcome the long-term preparation period and high levels of R&D and commercialization costs in terms of the limitations that the existing technology valuation method possesses by enhancing the reliability of approximate economic values from the deep learning results based on financial data and completed valuation data. In addition, it is expected that technology marketing coordinators, researchers, and non-specialty business agents, not limited to valuation experts, can easily estimate the economic values of their patents or technologies, and they can be actively utilized in a technology-based company’s decision-making and technologically dependent financial activities.
Various simulation studies for wireless body area networks (WBANs) based on the IEEE 802.15.6 standard have recently been carried out. However, most of these studies have applied a simplified model without using any major components specific to IEEE 802.15.6, such as connection-oriented link allocations, inter-WBAN interference mitigation, or a two-hop star topology extension. Thus, such deficiencies can lead to an inaccurate performance analysis. To solve these problems, in this study, we conducted a comprehensive review of the major components of the IEEE 802.15.6 standard and herein present modeling strategies for implementing IEEE 802.15.6 MAC on an NS-3 simulator. In addition, we configured realistic network scenarios for a performance evaluation in terms of throughput, average delay, and power consumption. The simulation results prove that our simulation system provides acceptable levels of performance for various types of medical applications, and can support the latest research topics regarding the dynamic resource allocation, inter-WBAN interference mitigation, and intra-WBAN routing.
The financial valuation of a drug that is still under development is required for various purposes. The risk-adjusted net present value (r-NPV) method, which recently emerged in the biotech industry, uses the development attrition rate as a discount factor to reflect risk during each development phase. The r-NPV method was developed to overcome the disadvantages of the prevailing discounted cash flow and real options methods and considers drug type, as well as the stage of development in its approach. Using this method, the current study examines technology values in the biopharmaceutical industry and matches the clinical development periods and success rates of these new drugs by analyzing datasets from ClinicalTrials.gov and MedTrack DB. It thus provides support for an empirical valuation model for experts in the field. Notably, there is limited research on the attrition rate and development period of new substance drugs and the research results are not consistently presented. In addition to new substance drugs, further research is necessary to deepen understanding of the attrition rate and development period of biologically-based drugs because of their inherent physical and developmental differences. Similarly, research on performance specifics within drug class models would enable refinement of the model.
This research aimed to build a solid basis through analytic hierarchy process (AHP) analysis to develop a reliable and practical valuation model that reflects the characteristics of the biotech industry and propose a reference formula to estimate the license fee by drug class for potential business transactions. In this study, we reviewed 135 related studies and found 167 related determinants. We surveyed 25 or more specialists in the biopharmaceutical industries. The survey group consisted of National Research Institutes (‘Group 1’), Companies (‘Group 2’), and Government Agencies–Universities (‘Group 3’). The average of the total group and Group 3 showed the same tendency at a Level 3 ranking, where the priority in determining the license fee was arranged in the order of ‘the market factor, the technology factor, the financial factor, and the environmental factor’ in light of the factors, and ‘patent characteristics, licensee characteristics, and licensor characteristics’ for the characteristics. We noted that the patent characteristics were primarily significant in technology transactions and their contract fee in the groups (Total, Group 2 and Group 3), followed by licensee characteristics. In terms of the in-depth index, we noted that the development phase and attrition rate, intellectual property tradability, and licensee licensing experience, followed by quality of technology, were the most influential determinants.